Sutro Biopharma (STRO) Net Income (2017 - 2025)

Sutro Biopharma's Net Income history runs 9 years deep, the most recent figure standing at -$46.8 million for Q4 2025.

• In Q4 2025, Net Income fell 130.64% year-over-year to -$46.8 million; the TTM figure through Dec 2025 stood at -$180.4 million (down 7418.17% YoY), while the FY2025 annual figure was -$191.1 million, down 7861.62% from the prior year.
• Net Income came in at -$46.8 million for Q4 2025 at Sutro Biopharma, up from -$56.9 million in the prior quarter.
• In the past five years, Net Income ranged from a high of $152.6 million in Q4 2024 to a low of -$65.3 million in Q1 2025.
• A 5-year average of -$25.2 million and a median of -$38.3 million in 2021 frame the typical range for Net Income.
• Across the five-year window, Net Income slumped 322.82% in 2022 and jumped 391.29% in 2024, its largest moves.
• Sutro Biopharma's Net Income stood at -$38.1 million in 2021, then advanced by 9.26% to -$34.6 million in 2022, then soared by 189.8% to $31.1 million in 2023, then surged by 391.29% to $152.6 million in 2024, then slumped by 130.64% to -$46.8 million in 2025.
• According to Business Quant data, Net Income over the past three periods registered -$46.8 million, -$56.9 million, and -$11.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison